Jong‐Mu Sun

机构：Samsung Medical Center, Sungkyunkwan University · ORCID：0000-0001-9683-4111

发表论文 395 篇 · 总被引 12385 次 · h-index 58

代表论文

• Patritumab deruxtecan (HER3-DXd) in resistant EGFR -mutated ( EGFR m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. (2025 · Journal of Clinical Oncology · 被引 43)
• TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer (2024 · Future Oncology · 被引 20)
• Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor (2025 · Journal for ImmunoTherapy of Cancer · 被引 9)
• Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer (2024 · eLife · 被引 6)
• Perioperative Pembrolizumab for Locally Advanced Thymic Epithelial Tumors: A Single-Arm, Phase 2 Trial (2025 · Journal of Thoracic Oncology · 被引 3)
• Clinical utility of circulating tumor DNA profiling in detecting targetable fusions in non-small cell lung cancer (2024 · Frontiers in Oncology · 被引 2)